Amy Schacterle
About Amy Schacterle
Amy Schacterle, Ph.D., is Chief Regulatory Officer & Head of Quality at Acumen Pharmaceuticals (ABOS). She joined in November 2024 and is 58 years old . Her background includes senior regulatory and development leadership roles at Sage Therapeutics (2014–2024) and Sunovion Pharmaceuticals; she holds a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute and an M.S./Ph.D. in Biomedical Engineering from the University of Virginia . Company filings show she adopted a Rule 10b5-1 plan related to RSU tax-withholding sales; specific pay levels (salary/bonus/equity grant sizes) for her were not disclosed in the latest proxy .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Sage Therapeutics | SVP, R&D Strategy & Business Management | Apr 2020 – Nov 2024 | Led portfolio strategy, resource prioritization, and regulatory leadership . |
| Sage Therapeutics | Various leadership roles | Dec 2014 – Nov 2024 | Built and led Regulatory and Quality; contributed to approval of first-ever treatment specific for postpartum depression . |
| Sunovion Pharmaceuticals (formerly Sepracor) | Vice President, Regulatory Affairs | Not disclosed | Led development and commercial regulatory activities at Marlborough campus . |
External Roles
No public company directorships or external board roles for Schacterle are disclosed in the latest proxy or appointment materials .
Fixed Compensation
Base salary, target bonus %, and realized bonus for Schacterle are not disclosed in the 2025 DEF 14A or subsequent 8-Ks reviewed .
Performance Compensation
Specific incentive metrics/weighting/targets/payouts for Schacterle are not disclosed. Company context: ABOS annual bonuses are tied to corporate (R&D, operational effectiveness, brand) and, for some roles, individual objectives; 2024 corporate goal attainment was 119% for NEOs (illustrative of company framework, not Schacterle-specific) .
Equity Ownership & Alignment
- Rule 10b5-1 plan: On September 30, 2025, Schacterle adopted a trading plan authorizing broker sales sufficient to cover taxes, commissions, and fees associated with vesting of up to 8,800 RSUs granted to her, with potential sales from Jan 7, 2026 through Dec 29, 2028. This indicates routine “sell-to-cover” activity around vesting, not discretionary liquidation .
- Hedging/pledging: Company insider trading policy prohibits short sales, options, hedging transactions, and margin accounts in ABOS stock, reducing misalignment and leverage risk .
- Beneficial ownership: The 2025 proxy does not list Schacterle individually in the beneficial ownership table; NEOs and directors are enumerated, and “all current executive officers and directors as a group (13 persons)” beneficially owned 6,129,070 shares (9.3%) as of April 8, 2025 (context) .
Employment Terms
Schacterle’s employment agreement, severance, and change-in-control terms are not disclosed in the 2025 DEF 14A. Company context for NEOs: double-trigger change-in-control severance includes salary continuation (12–18 months), COBRA premiums (12–18 months), bonus multiples (up to 1.5x target for CEO; 1.0x for others), and accelerated vesting of time-based equity (illustrative of ABOS practice; not specific to Schacterle) .
Performance & Track Record
- Leadership impact: Recognized for leading global regulatory and quality activities across neurologic and psychiatric indications and all development stages; at Sage, helped build regulatory/quality organizations and led efforts toward approval of the first-ever treatment specific for postpartum depression .
- Role fit: Appointed to lead ABOS’s global regulatory interactions and quality oversight as the company advances sabirnetug in Phase 2 and evolves development strategy .
Investment Implications
- Compensation alignment and transparency: Lack of disclosed salary/bonus/equity grant sizes for Schacterle limits precision on pay-for-performance linkage; monitor future proxies and any Item 5.02 8-Ks for detailed terms .
- Insider selling pressure: The 10b5-1 plan indicates periodic sell-to-cover of up to 8,800 RSUs through 2028, creating modest, predictable vesting-related sales rather than discretionary selling—low incremental pressure in absolute terms .
- Alignment and governance: Company policy prohibiting hedging/margin aligns executive exposure with shareholders and reduces risk of adverse incentives; absence of disclosed pledging is positive .
- Retention risk: ABOS NEO severance framework (context) is market-standard with double-trigger protections; while Schacterle’s terms are not disclosed, her seniority and role significance argue for monitoring retention (e.g., equity refresh cadence, vesting timelines) via future filings .